Research Progress on the Risk of Excipients-Related Adverse Reactions in Pharmaceutical Preparations for IBD Treatment
- VernacularTitle:炎症性肠病治疗药物辅料相关不良反应的研究进展
- Author:
Yanru ZHANG
1
;
Qiuyue TU
1
;
Ping WANG
2
;
Zelin FENG
1
;
Huizhen LI
1
;
Yushan ZHU
3
;
Haojia LIN
1
;
Xinyue WEI
1
;
Qinghua YI
1
;
Hetong ZHANG
1
;
Yueting LI
1
;
Xiaoqin LI
1
;
Yu WANG
1
;
Dong XIE
4
;
Xiaocang CAO
5
Author Information
- Publication Type:Review
- Keywords: inflammatory bowel disease; pharmaceutical excipients; adverse reactions; clinical management; preventive strategies
- From: Medical Journal of Peking Union Medical College Hospital 2026;17(4):1135-1142
- CountryChina
- Language:Chinese
-
Abstract:
Patients with inflammatory bowel disease (IBD) require long-term pharmacotherapy. Due to the wide variety of clinically available drugs, medication safety has become increasingly concerning. As an indispensable component of pharmaceutical formulations, drug excipients may induce various adverse reactions, including rash, allergic responses, and gastrointestinal discomfort, and may even lead to severe organic injury. However, they are often overlooked in clinical practice. Therefore, identifying and managing excipient-related adverse reactions is crucial for ensuring medication safety. To address this issue, this article systematically reviews common excipients in IBD therapeutics, the underlying mechanisms of excipient-induced adverse reactions, and corresponding management strategies, aiming to enhance clinicians' awareness of excipient-related issues, improve their ability to recognize and manage such reactions, and ultimately ensure patient safety.
